Antifibrotic effects of ambrisentan, an endothelin-A receptor antagonist, in a non-alcoholic steatohepatitis mouse model

Table 1 Effects of ambrisentan administration on various parameters in fatty liver shionogi-ob/ob mice

Parameters	Control group (n = 5)	Ambrisentan group (n = 8)	P value
Body weight (g)	47.3 ± 3.6	47.0 ± 4.6	0.27
Liver weight (g)	5.4 ± 1.2	5.1 ± 1.1	0.75
Liver/body weight ratio	0.11 ± 0.02	0.11 ± 0.01	0.68
Visceral fat weight (g)	2.5 ± 0.3	2.7 ± 0.3	0.32
Weekly dietary intake (g)	31.7 ± 9.3	29.4 ± 9.0	0.66
Serum AST (U/L)	143 ± 20	155 ± 43	0.59
Serum ALT (U/L)	120 ± 52	151 ± 65	0.38
Hepatic cholesterol (mg/dL)	24.5 ± 1.56	27.2 ± 2.58	0.06
Hepatic triglyceride (mg/dL)	1152 ± 500	929 ± 210	0.28

AST: Aspartate aminotransferase; ALT: Alanine aminotransferase.